Literature DB >> 17546960

A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer.

E A Bogush1, A B Ravcheeva, T A Bogush, T N Zabotina, Z G Kadagidze, M I Davydov.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17546960     DOI： 10.1134/s1607672907020123

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


× No keyword cloud information.
  11 in total

1.  Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells.

Authors:  S Batra; R Karlsson; L Witt
Journal:  Int J Cancer       Date:  1996-11-27       Impact factor: 7.396

2.  Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.

Authors:  R De Vincenzo; G Scambia; P Benedetti Panici; A Fattorossi; G Bonanno; C Ferlini; G Isola; S Pernisco; S Mancuso
Journal:  Int J Cancer       Date:  1996-11-04       Impact factor: 7.396

3.  A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer.

Authors:  Y M Chen; R P Perng; K Y Yang; W C Lin; H W Wu; J M Liu; C M Tsai; J Whang-Peng
Journal:  Am J Clin Oncol       Date:  2000-02       Impact factor: 2.339

4.  High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma.

Authors:  C H Yang; A L Cheng; K H Yeh; C J Yu; J F Lin; P C Yang
Journal:  Cancer       Date:  1999-08-01       Impact factor: 6.860

5.  Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells.

Authors:  T Hotta; H Tanimura; H Yamaue; M Iwahashi; M Tani; T Tsunoda; M Tamai; K Noguchi; S Mizobata; K Arii; H Terasawa
Journal:  J Surg Res       Date:  1996-11       Impact factor: 2.192

6.  Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo.

Authors:  Li-Zong Shen; Yi-Bing Hua; Xue-Ming Yu; Qing Xu; Tao Chen; Jian-Hua Wang; Wen-Xi Wu
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

7.  Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells.

Authors:  A R Safa; S Roberts; M Agresti; R L Fine
Journal:  Biochem Biophys Res Commun       Date:  1994-07-15       Impact factor: 3.575

8.  Antiestrogens and steroid hormones: substrates of the human P-glycoprotein.

Authors:  U S Rao; R L Fine; G A Scarborough
Journal:  Biochem Pharmacol       Date:  1994-07-19       Impact factor: 5.858

9.  Interaction of tamoxifen with the multidrug resistance P-glycoprotein.

Authors:  R Callaghan; C F Higgins
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

10.  Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites.

Authors:  J Kirk; S Houlbrook; N S Stuart; I J Stratford; A L Harris; J Carmichael
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640
View more
  3 in total

1.  MRP as a new predictive marker of tamoxifen efficiency in treatment of estrogen receptor-positive breast cancer.

Authors:  T A Bogush; E A Dudko; E A Bogush; M V Tikhomirov; V Yu Kirsanov; M I Davydov
Journal:  Dokl Biochem Biophys       Date:  2010 Jan-Feb       Impact factor: 0.788

Review 2.  Tamoxifen non-estrogen receptor mediated molecular targets.

Authors:  Tatiana Bogush; Evgeny Dudko; Elena Bogush; Boris Polotsky; Sergei Tjulandin; Mikhail Davydov
Journal:  Oncol Rev       Date:  2012-10-04

Review 3.  Tamoxifen and oxidative stress: an overlooked connection.

Authors:  Nermin S Ahmed; Marek Samec; Alena Liskova; Peter Kubatka; Luciano Saso
Journal:  Discov Oncol       Date:  2021-05-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.